861 related articles for article (PubMed ID: 28270497)
21. Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study.
Masuda N; Nishimura R; Takahashi M; Inoue K; Ohno S; Iwata H; Mori Y; Hashigaki S; Muramatsu Y; Nagasawa T; Umeyama Y; Toi M
Cancer Sci; 2018 Mar; 109(3):803-813. PubMed ID: 29345736
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
Hurvitz SA; Bardia A; Quiroga V; Park YH; Blancas I; Alonso-Romero JL; Vasiliev A; Adamchuk H; Salgado M; Yardley DA; Berzoy O; Zamora-Auñón P; Chan D; Spera G; Xue C; Ferreira E; Badovinac Crnjevic T; Pérez-Moreno PD; López-Valverde V; Steinseifer J; Fernando TM; Moore HM; Fasching PA;
Lancet Oncol; 2023 Sep; 24(9):1029-1041. PubMed ID: 37657462
[TBL] [Abstract][Full Text] [Related]
23. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
Mangini NS; Wesolowski R; Ramaswamy B; Lustberg MB; Berger MJ
Ann Pharmacother; 2015 Nov; 49(11):1252-60. PubMed ID: 26324355
[TBL] [Abstract][Full Text] [Related]
24. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
25. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
26. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer.
Cottu P; D'Hondt V; Dureau S; Lerebours F; Desmoulins I; Heudel PE; Duhoux FP; Levy C; Mouret-Reynier MA; Dalenc F; Frenel JS; Jouannaud C; Venat-Bouvet L; Nguyen S; Ferrero JM; Canon JL; Grenier J; Callens C; Gentien D; Lemonnier J; Vincent-Salomon A; Delaloge S
Ann Oncol; 2018 Dec; 29(12):2334-2340. PubMed ID: 30307466
[TBL] [Abstract][Full Text] [Related]
27. Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial.
Ciruelos E; Villagrasa P; Pascual T; Oliveira M; Pernas S; Paré L; Escrivá-de-Romaní S; Manso L; Adamo B; Martínez E; Cortés J; Vazquez S; Perelló A; Garau I; Melé M; Martínez N; Montaño A; Bermejo B; Morales S; Echarri MJ; Vega E; González-Farré B; Martínez D; Galván P; Canes J; Nuciforo P; Gonzalez X; Prat A
Clin Cancer Res; 2020 Nov; 26(22):5820-5829. PubMed ID: 32938620
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Saura C; Hlauschek D; Oliveira M; Zardavas D; Jallitsch-Halper A; de la Peña L; Nuciforo P; Ballestrero A; Dubsky P; Lombard JM; Vuylsteke P; Castaneda CA; Colleoni M; Santos Borges G; Ciruelos E; Fornier M; Boer K; Bardia A; Wilson TR; Stout TJ; Hsu JY; Shi Y; Piccart M; Gnant M; Baselga J; de Azambuja E
Lancet Oncol; 2019 Sep; 20(9):1226-1238. PubMed ID: 31402321
[TBL] [Abstract][Full Text] [Related]
29. Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.
Johnston S; Puhalla S; Wheatley D; Ring A; Barry P; Holcombe C; Boileau JF; Provencher L; Robidoux A; Rimawi M; McIntosh SA; Shalaby I; Stein RC; Thirlwell M; Dolling D; Morden J; Snowdon C; Perry S; Cornman C; Batten LM; Jeffs LK; Dodson A; Martins V; Modi A; Osborne CK; Pogue-Geile KL; Cheang MCU; Wolmark N; Julian TB; Fisher K; MacKenzie M; Wilcox M; Huang Bartlett C; Koehler M; Dowsett M; Bliss JM; Jacobs SA
J Clin Oncol; 2019 Jan; 37(3):178-189. PubMed ID: 30523750
[TBL] [Abstract][Full Text] [Related]
30. Palbociclib: first global approval.
Dhillon S
Drugs; 2015 Apr; 75(5):543-51. PubMed ID: 25792301
[TBL] [Abstract][Full Text] [Related]
31. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
DeMichele A; Clark AS; Tan KS; Heitjan DF; Gramlich K; Gallagher M; Lal P; Feldman M; Zhang P; Colameco C; Lewis D; Langer M; Goodman N; Domchek S; Gogineni K; Rosen M; Fox K; O'Dwyer P
Clin Cancer Res; 2015 Mar; 21(5):995-1001. PubMed ID: 25501126
[TBL] [Abstract][Full Text] [Related]
32. Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer.
Madeira M; Mattar A; Logullo AF; Soares FA; Gebrim LH
BMC Cancer; 2013 Sep; 13():425. PubMed ID: 24047421
[TBL] [Abstract][Full Text] [Related]
33. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).
Verma S; Bartlett CH; Schnell P; DeMichele AM; Loi S; Ro J; Colleoni M; Iwata H; Harbeck N; Cristofanilli M; Zhang K; Thiele A; Turner NC; Rugo HS
Oncologist; 2016 Oct; 21(10):1165-1175. PubMed ID: 27368881
[TBL] [Abstract][Full Text] [Related]
34. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial.
Harbeck N; Iyer S; Turner N; Cristofanilli M; Ro J; André F; Loi S; Verma S; Iwata H; Bhattacharyya H; Puyana Theall K; Bartlett CH; Loibl S
Ann Oncol; 2016 Jun; 27(6):1047-1054. PubMed ID: 27029704
[TBL] [Abstract][Full Text] [Related]
35. Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer.
Yamamoto T; Kanaya N; Somlo G; Chen S
Breast Cancer Res Treat; 2019 Apr; 174(3):615-625. PubMed ID: 30607633
[TBL] [Abstract][Full Text] [Related]
36. Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells.
Kishino E; Ogata R; Saitoh W; Koike Y; Ohta Y; Kanomata N; Kurebayashi J
Breast Cancer; 2020 May; 27(3):415-425. PubMed ID: 31823286
[TBL] [Abstract][Full Text] [Related]
37. Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER
Dowsett M; Kilburn L; Rimawi MF; Osborne CK; Pogue-Geile K; Liu Y; Jacobs SA; Finnigan M; Puhalla S; Dodson A; Martins V; Cheang M; Perry S; Holcombe C; Turner N; Swift C; Bliss JM; Johnston S;
Clin Cancer Res; 2022 Jan; 28(1):163-174. PubMed ID: 34645649
[TBL] [Abstract][Full Text] [Related]
38. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Fribbens C; O'Leary B; Kilburn L; Hrebien S; Garcia-Murillas I; Beaney M; Cristofanilli M; Andre F; Loi S; Loibl S; Jiang J; Bartlett CH; Koehler M; Dowsett M; Bliss JM; Johnston SR; Turner NC
J Clin Oncol; 2016 Sep; 34(25):2961-8. PubMed ID: 27269946
[TBL] [Abstract][Full Text] [Related]
39. Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.
Curigliano G; Gómez Pardo P; Meric-Bernstam F; Conte P; Lolkema MP; Beck JT; Bardia A; Martínez García M; Penault-Llorca F; Dhuria S; Tang Z; Solovieff N; Miller M; Di Tomaso E; Hurvitz SA
Breast; 2016 Aug; 28():191-8. PubMed ID: 27336726
[TBL] [Abstract][Full Text] [Related]
40. CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer.
Zhang K; Hong R; Kaping L; Xu F; Xia W; Qin G; Zheng Q; Lu Q; Zhai Q; Shi Y; Yuan Z; Deng W; Chen M; Wang S
Cancer Lett; 2019 Apr; 447():130-140. PubMed ID: 30677445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]